File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.cgh.2012.03.016
- Scopus: eid_2-s2.0-84865319280
- PMID: 22475742
- WOS: WOS:000308578400020
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B
Title | High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B |
---|---|
Authors | |
Keywords | Antiviral Therapy Hepatitis B Virus Nucleos(T)Ide Analogue |
Issue Date | 2012 |
Publisher | WB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh |
Citation | Clinical Gastroenterology And Hepatology, 2012 How to Cite? |
Abstract | There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB. © 2012 AGA Institute. |
Persistent Identifier | http://hdl.handle.net/10722/163490 |
ISSN | 2023 Impact Factor: 11.6 2023 SCImago Journal Rankings: 3.091 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pan, CQ | en_US |
dc.contributor.author | Tong, M | en_US |
dc.contributor.author | Kowdley, KV | en_US |
dc.contributor.author | Hu, K | en_US |
dc.contributor.author | Chang, T | en_US |
dc.contributor.author | Lai, C | en_US |
dc.contributor.author | Yoon, SK | en_US |
dc.contributor.author | Lee, SS | en_US |
dc.contributor.author | Cohen, D | en_US |
dc.contributor.author | Tang, H | en_US |
dc.contributor.author | Tsai, N | en_US |
dc.date.accessioned | 2012-09-05T05:32:07Z | - |
dc.date.available | 2012-09-05T05:32:07Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | Clinical Gastroenterology And Hepatology, 2012 | en_US |
dc.identifier.issn | 1542-3565 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163490 | - |
dc.description.abstract | There are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB. © 2012 AGA Institute. | en_US |
dc.language | eng | en_US |
dc.publisher | WB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh | en_US |
dc.relation.ispartof | Clinical Gastroenterology and Hepatology | en_US |
dc.subject | Antiviral Therapy | en_US |
dc.subject | Hepatitis B Virus | en_US |
dc.subject | Nucleos(T)Ide Analogue | en_US |
dc.title | High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lai, C:hrmelcl@hku.hk | en_US |
dc.identifier.authority | Lai, C=rp00314 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.cgh.2012.03.016 | en_US |
dc.identifier.pmid | 22475742 | - |
dc.identifier.scopus | eid_2-s2.0-84865319280 | en_US |
dc.identifier.hkuros | 208887 | - |
dc.identifier.isi | WOS:000308578400020 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Pan, CQ=8431195300 | en_US |
dc.identifier.scopusauthorid | Tong, M=7202033792 | en_US |
dc.identifier.scopusauthorid | Kowdley, KV=26643305700 | en_US |
dc.identifier.scopusauthorid | Hu, K=55213827000 | en_US |
dc.identifier.scopusauthorid | Chang, T=7404725147 | en_US |
dc.identifier.scopusauthorid | Lai, C=7403086396 | en_US |
dc.identifier.scopusauthorid | Yoon, SK=7404036291 | en_US |
dc.identifier.scopusauthorid | Lee, SS=7601405566 | en_US |
dc.identifier.scopusauthorid | Cohen, D=35475416000 | en_US |
dc.identifier.scopusauthorid | Tang, H=55214347700 | en_US |
dc.identifier.scopusauthorid | Tsai, N=7006824415 | en_US |
dc.identifier.issnl | 1542-3565 | - |